The CARMA study – treating lymphoma with new 'armed' CAR T cells
A new "first-in-human" study with enhanced CAR-T cells will start at KFUE's Phase 1 unit at Uppsala University Hospital in spring 2024.
The CARMA study – treating lymphoma with new 'armed' CAR T cells
A new "first-in-human" study with enhanced CAR-T cells will start at KFUE's Phase 1 unit at Uppsala University Hospital in spring 2024.
The CAR-T cells are developed in Prof. Magnus Essand's research group and Gunilla Enblad is the principal investigator for the study. Listen to Gunilla when she talks about the study in the movie clip below.
The CAR T cells target CD20 and when they attack the cancer cells, they secrete the immunostimulant NAP (neutrophil activating protein from Helicobacter Pylori) which can induce a broad immunological attack on the tumor. Lymphoma patients who cannot be treated with already approved CD19-targeted CAR T cells (Yescarta) and lymphoma patients who have relapsed after treatment with Yescarta will be included in the study. Uppsala University together with Elicera Therapeutics is the sponsor of the study.
Article in Nature Biomedical Engineering
An article describing the creation of CAR(NAP)-T cells and how they work was published in 2022 in Nature Biomedical Engineering.
Link to the article: https://www.nature.com/articles/s41551-022-00875-5
Contact
Read more about the research groups at Uppsala University.
Gunilla Enblad – Tumour biology and clinical studies of lymphomas and prostate cancer (uu.se)
Magnus Essand – Cancer immunotherapy (uu.se)
The phase 1 unit at the clinical research and development unit (KFUE)